PharmaCyte Biotech Files Definitive Proxy Statement
Ticker: PMCB · Form: DEF 14A · Filed: Mar 10, 2025 · CIK: 1157075
| Field | Detail |
|---|---|
| Company | Pharmacyte Biotech, Inc. (PMCB) |
| Form Type | DEF 14A |
| Filed Date | Mar 10, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, regulatory-filing, shareholder-meeting
TL;DR
PharmaCyte Biotech filed its DEF 14A proxy statement on 3/10/25. Standard shareholder meeting stuff.
AI Summary
PharmaCyte Biotech, Inc. filed a Definitive Proxy Statement (DEF 14A) on March 10, 2025, for the fiscal year ending April 30, 2025. The filing, with accession number 0001683168-25-001464, concerns the company's proxy materials, which are typically related to shareholder meetings and voting on corporate matters. The company is incorporated in Nevada and its principal executive offices are located in Laguna Hills, California.
Why It Matters
This filing is a standard regulatory requirement for public companies, providing shareholders with information necessary to vote on important corporate matters at upcoming meetings.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new financial or operational information that would inherently increase risk.
Key Numbers
- 20250310 — Filing Date (Date the DEF 14A was filed with the SEC.)
- 20250424 — Period of Report (The fiscal period the proxy statement pertains to.)
Key Players & Entities
- PharmaCyte Biotech, Inc. (company) — Registrant
- 0001683168-25-001464 (filing_id) — Accession Number
- 20250310 (date) — Filing Date
- 20250424 (date) — Period of Report
- 23046 AVENIDA DE LA CARLOTA, SUITE 600 (address) — Business Address
- LAGUNA HILLS, CA (location) — Business Location
- NUVILEX, INC. (company) — Former Company Name
- EFOODSAFETY COM INC (company) — Former Company Name
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, or Definitive Proxy Statement, is used by companies to solicit proxies from shareholders for an upcoming shareholder meeting, providing details on matters to be voted upon.
When was this specific DEF 14A filing made by PharmaCyte Biotech, Inc.?
PharmaCyte Biotech, Inc. filed this DEF 14A on March 10, 2025.
What is the fiscal year end for PharmaCyte Biotech, Inc.?
The fiscal year end for PharmaCyte Biotech, Inc. is April 30.
Where are PharmaCyte Biotech, Inc.'s principal executive offices located?
PharmaCyte Biotech, Inc.'s principal executive offices are located at 23046 Avenida de la Carlota, Suite 600, Laguna Hills, CA 92653.
Has PharmaCyte Biotech, Inc. operated under any previous names?
Yes, PharmaCyte Biotech, Inc. previously operated under the names NUVILEX, INC. and EFOODSAFETY COM INC.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on March 10, 2025 regarding PharmaCyte Biotech, Inc. (PMCB).